INTRODUCTION
The group of conditions collectively termed retinitis pigmentosa (RP) is both clinically and genetically heterogeneous (1, 2) . Major features of the condition are early nyctalopia (night blindness) owing to dysfunction and death of the rod photoreceptor cells, a symptom usually followed by narrowing of the visual fields due to the subsequent loss of the cone photoreceptors. Intraretinal pigmentary deposits are often seen as the disease progresses (for reviews, see refs 3 and 4). RP currently affects up to 1.5 million people world-wide, in most cases resulting in significant visual handicap. Up to 50% of cases are sporadic, the remainder segregating in an autosomal dominant, recessive or X-linked recessive mode. Approximately 40 genetic loci involved in the aetiology of the disease or of syndromes incorporating the disease have been identified, largely as a result of genetic linkage studies, and up to 15 genes have been identified (http://www.sph.uth.tmc.edu/retnet/ ). The majority of proteins encoded by such genes are expressed within the photoreceptor cells and are components either of the visual transduction cycle or structural components of these cells. The localization of the first gene to be implicated in autosomal dominant RP (adRP) on the long arm of chromosome 3 was reported in 1989 (5, 6) . The gene encoding rhodopsin, the primary photoreactive pigment of the rod photoreceptor cells, had previously been shown to map within this region of the genome, and a mutation within that gene, P23H, was subsequently identified in a family with RP (7). To date, at least 90 mutations have been identified within the rhodopsin gene, the majority in adRP, although a few mutations implicated in recessive forms of the disease or in congenital night blindness have also been identified (8) (9) (10) (11) (12) .
Rhodopsin is the most abundantly expressed protein of the rod photoreceptor cells (13) . The characterization of a mouse model for degenerative retinal disease, based upon the targeted disruption of the rhodopsin gene, was reported by this team and its collaborators in 1997 (14) and further electroretinographic studies on such animals have been reported recently (15) . Rho-/-mice do not elaborate rod photoreceptor outer segments (ROS); the rod electroretinogram (ERG) is unrecordable and the photoreceptor layer is reduced to a single row of nuclei, probably representing those derived exclusively from cone cells, over a period of~3 months. In order to fully exploit the utility of these animals in the development of methods for the re-introduction to ocular tissues of functional rhodopsin genes in man, or in the development of suppression effectors of dominant mutations within the human rhodopsin gene, it would be of value to assess the ability of human rhodopsin to rescue the retinopathy in such mice.
Murine and human rhodopsins differ in their amino acid sequences at 18 residues. Interestingly, inter-species variability is seen around the chromophore-binding lysine at codon 296, an area that arguably would be expected to be significantly conserved. Whether, or to what extent, such variability has any influence on the ability of human rhodopsin to couple with similar efficiency as that of the endogenous protein to the signal transduction system of the mouse and thus effectively rescue the photoreceptors of Rho-/-mice, or to perform as an adequate structural substitute in the mouse ROS, requires formal establishment. Here we report the results of experiments in which Rho-/-mice were crossed onto a transgenic strain of mouse expressing wild-type human rhodopsin protein at levels which approximate to those normally existing in the mouse retina (16) . Histopathological, immunological and electroretinographic data are presented which demonstrate extensive structural and functional rescue of the mouse photoreceptors by the human transgene.
RESULTS AND DISCUSSION
Mice carrying a targeted disruption of the rhodopsin gene show a steady decline of photoreceptor numbers with age. At 90 days, the outer nuclear layer (ONL) is reduced to only a single layer of cells, which are primarily surviving cone photoreceptors. Using immunocytochemical techniques, rhodopsin is undetectable within the degenerating photoreceptor layer at any time, and even young Rho-/-mice have no rod-driven ERG responses (14) .
Sections of retinas of 3-month-old Rho+/+ and Rho-/-mice, and of mice expressing the human rhodopsin transgene, are shown in Figure 1 . At this age, Rho-/-mice have lost essentially all of their photoreceptors. In terms of numbers of nuclei within the ONL, and of morphology of inner and outer segments of the photoreceptors, wild-type retinas and retinas rescued by the human transgene were indistinguishable.
Immunocytochemical studies were performed on cryosectioned retinas using a fluorescent anti-rhodopsin antibody, 4D2, kindly supplied by Drs Robert and Lauri Molday. This antibody recognizes an epitope at the N-terminus of the rhodopsin protein. No immunoreactivity was detectable in retinal sections of Rho-/-mice at any stage of development. No reactivity was detectable in the retinas of wild-type and rescued mice at 1 day of age, but was clearly visible at day 3 ( Fig. 2) . At 3 months, immunofluorescence was confined exclusively to the ROS in both wild-type and transgene-rescued retinas (Fig.   2) . The results obtained from wild-type and rescued retinas were similar. Figure 3 shows a typical dark-adapted ERG series recorded over 6.4 log units of flash intensity for the wild-type (left) and the transgenic mice (right). The normal negative a-wave and positive b-wave responses are seen for bright flashes at the bottom of the figure. The dimmest flashes primarily show the positive b-wave and a negativity that is the scotopic threshold response from the proximal retina. For both groups, the ERG threshold of 10 µV is at approximately -5.14 log candela/s/m2 (cd-s/m2). The homozygous Rho-/-mice had no detectable ERG response for any stimulus, including the brightest flash for both dark-and light-adapted conditions. Figure 4 shows the intensity-response functions for the normal wild-type and the transgenic mice. The wild-type mice have slightly larger b-wave amplitudes than transgenic mice at intensities above -1 log cd-s/m2, but the amplitude difference is not significant. The maximum b-wave amplitude measured at a flash intensity level of 0.61 log cd-s/m2 was 792 ± 488 µV for the wild-type mice and 616 ± 184 µV for the transgenic mice (Table 1 ; P = 0.52 by a two-tailed student t-test). A 50 µV criterion was used to identify b-wave threshold, and the corresponding flash intensity level was measured from the intensity-response curve for each animal. The mean b-wave threshold for normal mice was -3.99 ± 0.75 log cd-s/m2 and the mean for the transgenic mice was -4.00 ± 0.14 log cd-s/m2, which is not significantly different for the two groups (Table 1 ; P = 0.93 by a two-tailed t-test). The maximum amplitude of the cone-driven photopic ERG for a 0.61 log cd-s/m2 flash was 150 ± 71 µV for the wild-types and 155 ± 112 µV for the transgenic mice and was not significantly different (P = 0.94 by a two-tailed t-test).
Wild-type animals used in this investigation had rod thresholds quite similar to those reported previously for wild-type mice (15) . The same study found that the dark-adapted b-wave threshold of Rho-/-mice was at -1.07 log cd-s/m2 for animals younger than 6 weeks of age; since this represents cone threshold, all Rho-/-responses at dimmer intensities must be rod driven (15) . By 12 weeks of age, the retinal degeneration in the Rho-/-mouse resulted in no detectable ERG even with bright flashes. The transgenic animals, however, have thresholds 3.0 log units more sensitive than the cone dark-adapted b-wave threshold of Rho-/-mice in the previous studies (14, 15) , indicating that the human rhodopsin transgene against a Rho-/-background has rescued rod function. Furthermore, these recordings were made in 20-week-old mice, by which age the Rho-/-animals have no detectable response, both in the current and in the previous studies (14, 15) .
In summary, the histopathological, immunocytochemical and electrophysiological data presented here demonstrate a substantial structural and functional rescue of rod cells in the Rho-/-mouse retina by crossing onto a transgenic strain of mouse expressing the human rhodopsin gene. This information is required for optimal use of Rho-/-mice in exploring methods for suppressing human degenerative retinal conditions whose molecular pathologies are based either upon loss of rhodopsin gene function or on the manifestation of dominant mutations within that gene.
MATERIALS AND METHODS
Methods for genotypic analysis of Rho-/-mice based on amplification of tail DNAs have been described previously (16) . Mice homozygous for the presence of a human rhodopsin transgene were kindly made available by Dr T. Dryja (IMA Eye and Ear Infirmary, Boston, MA) (16) . In this line of transgenic mouse, levels of the human opsin approximate to those of the endogenous protein in the wild-type mouse. Primers specific for amplification of exon 5 of the human rhodopsin gene were: sense, 5'-TTCCAAGCACACTGTGGGCA-3'; and antisense, 5'-TGTGACTTCGTTCATTCTGC-3'. A 25 µl PCR reaction mix contained 100 ng DNA, 50 pmol sense and antisense primers, 200 µM each of dGTP, dATP, dTTP and dCTP, 1.5 mM MgCl2, 100 mM Tris, pH 9, 50 mM KCl, 1× Triton and 0.75 U Taq polymerase. PCR conditions were 94°C for 1 min, 55°C for 1 min and 72°C for 1.2 min, for 30 cycles. The amplification product obtained with these primers is 274 bp in length. Rho-/-mice were crossed with mice homozygous for the human rhodopsin transgene. F1s, heterozygous for both the mouse and human rhodopsin genes, were self crossed, and those of genotype Rho-/-and carrying either one or two copies of the human rhodopsin transgene were identified for use in the present study (note that the assay for the human opsin gene does not discriminate between animals heterozygous or homozygous for the human gene).
Methods for histopathological, immunocytochemical and electroretinographic analyses of mouse retinas have been described previously (14) .
